-

Exact Sciences to Participate in March Investor Conferences

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

  • TD Cowen Health Care Conference, Boston
    Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET
  • Raymond James Institutional Investors Conference, Orlando
    Presentation on Tuesday, March 4, 2025 at 1:05 p.m. ET

The webcasts can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contacts

Derek Leckow
Exact Sciences Corp.
investorrelations@exactsciences.com
608-893-0009

Industry:

Exact Sciences Corp.

NASDAQ:EXAS
Release Versions
English

Contacts

Derek Leckow
Exact Sciences Corp.
investorrelations@exactsciences.com
608-893-0009

More News From Exact Sciences Corp.

PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis

MARSHFIELD, Wis.--(BUSINESS WIRE)--PreventionGenetics, a wholly owned subsidiary of Exact Sciences Corp., announced that it is the new administrator of Alnylam Act,® a sponsored genetic testing program by Alnylam Pharmaceuticals, Inc. The program, called Alnylam Act®, provides genetic testing for the diagnosis of acute hepatic porphyria, primary hyperoxaluria type 1 (PH1), and hereditary ATTR (hATTR) amyloidosis. Along with genetic testing, the program includes access to pre and post-test genet...

Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition. This award recognizes the most engaged workplace cultures in the world. Gallup created the Exceptional Workplace Award to identify excellence and celebrate organizations that incorporate employee e...

New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX® Test on Patient Care and Healthcare Efficiency

BAAR, Switzerland--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score® test at the 19th St. Gallen International Breast Cancer Conference in Vienna, Austria. A UK study1 explored the benefits of shifting the testing point to the pre-surgery setting by utilizing Oncotype DX on breast cancer core biopsy samples instead of surgical speci...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.